Orgaran in heparin-induced thrombocytopenia

Area of Science:

• Pharmacology
• Hematology
• Thrombosis Research

Background:

• Heparin-induced thrombocytopenia (HIT) necessitates alternative anticoagulation due to thromboembolic risks.
• Low-molecular-weight heparins (LMWH) exhibit significant in vitro cross-reactivity with HIT antibodies (approx. 80%).
• Orgaran (Org 10172), a low-molecular-weight glycosaminoglycuronan, shows reduced cross-reactivity with HIT antibodies (10%).

Purpose of the Study:

• To evaluate the safety and efficacy of Orgaran in Australian patients diagnosed with HIT.
• To assess Orgaran's effectiveness in various clinical scenarios including thromboembolic treatment and prophylaxis.
• To confirm Orgaran's low cross-reactivity profile with HIT antibodies.

Main Methods:

• Retrospective analysis of 57 Australian patients treated with intravenous or subcutaneous Orgaran.
• Diagnosis of HIT confirmed by exclusion of other causes and objective testing.
• Data collection on presenting indications, treatment outcomes, and adverse events.

Main Results:

• Orgaran treatment was successful in over 90% of patients.
• The drug was safe and well-tolerated, even in critically ill patients requiring haemofiltration.
• Low cross-reactivity (12%) with HIT serum factor was confirmed in a global study of 161 patients.

Conclusions:

• Orgaran is a safe, effective, and well-tolerated anticoagulant for patients with HIT.
• Its low cross-reactivity profile makes it a valuable therapeutic option for HIT patients at high risk of thrombosis or bleeding.
• Orgaran offers a viable alternative to heparin in managing HIT patients, including those with critical illness.